Genetic reduction of circulating insulin-like growth factor-1 inhibits azoxymethane-induced colon tumorigenesis in mice

Molecular Carcinogenesis

Volumn 48, Issue 12, 2009, Pages 1071-1076

  Olivo Marston, Susan E ^a   Hursting, Stephen D ^b,c   Lavigne, Jackie ^a   Perkins, Susan N ^b   Maarouf, Rami S ^a   Yakar, Shoshana ^d   Harris, Curtis C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Azoxymethane; Colon; IGF 1

Indexed keywords

AZOXYMETHANE; CRE RECOMBINASE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; SOMATOMEDIN C; TUMOR NECROSIS FACTOR ALPHA; CARCINOGEN; INSULIN LIKE GROWTH FACTOR 1, MOUSE; INSULIN-LIKE GROWTH FACTOR-1, MOUSE; INTEGRASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BODY WEIGHT; CELL PROLIFERATION; COLON ADENOCARCINOMA; COLON CARCINOGENESIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; GENE DELETION; LOXP SITE; MOUSE; NONHUMAN; PRIORITY JOURNAL; WILD TYPE; ANIMAL; CHEMICALLY INDUCED DISORDER; COLON TUMOR; ENZYME IMMUNOASSAY; LIVER; METABOLISM; MOUSE MUTANT; PHYSIOLOGY; TRANSGENIC MOUSE;

MUS;

ANIMALS; APOPTOSIS; AZOXYMETHANE; CARCINOGENS; CELL PROLIFERATION; COLONIC NEOPLASMS; IMMUNOENZYME TECHNIQUES; INSULIN-LIKE GROWTH FACTOR I; INTEGRASES; LIVER; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC;

EID: 73349105273     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.20577     Document Type: Article

References (31)

1. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: Biological actions. Endocr Rev 1995;16:3-34.
2. Liu JL, LeRoith D. Insulin-like growth factor I is essential for postnatal growth in response to growth hormone. Endocrinology 1999;140:5178-5184.
3. Liu JL, Grinberg A, Westphal H, et al. Insulin-like growth factor-I affects perinatal lethality and postnatal development in a gene dosage-dependent manner: Manipulation using the Cre/loxP system in transgenic mice. Mol Endocrinol 1998;12:1452-1462.
4. Liu JP, Baker J, Perkins AS, Robertson EJ, Efstratiadis A. Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r). Cell 1993;75:59-72.
5. Bartlett WP, Li XS, Williams M, Benkovic S. Localization of insulin-like growth factor-1 mRNA in murine central nervous system during postnatal development. Dev Biol 1991;147:239-250.
6. Laron Z. Insulin-like growth factor 1 (IGF-1): A growth hormone. Mol Pathol 2001;54:311-316.
7. LeRoith D, Baserga R, Helman L, Roberts CT, Jr. Insulin-like growth factors and cancer. Ann Intern Med 1995;122:54-59.
8. Butler AA, Yakar S, Gewolb IH, Karas M, Okubo Y, LeRoith D. Insulin-like growth factor-I receptor signal transduction: At the interface between physiology and cell biology. Comp Biochem Physiol B Biochem Mol Biol 1998;121:19-26.
9. Allen RT, Krueger KD, Dhume A, Agrawal DK. Sustained Akt/ PKB activation and transient attenuation of c-jun N-terminal kinase in the inhibition of apoptosis by IGF-1 in vascular smooth muscle cells. Apoptosis 2005;10:525-535.
10. Kundu AK, Nagaoka M, Chowdhury EH, Hirose S, Sasagawa T, Akaike T. IGF-1 induces growth, survival and morphological change of primary hepatocytes on a galactose-bared polymer through both MAPK and beta-catenin pathways. Cell Struct Funct 2003;28:255-263.
11. Nitta A, Zheng WH, Quirion R. Insulin-like growth factor 1 prevents neuronal cell death induced by corticosterone through activation of the PI3k/Akt pathway. J Neurosci Res 2004;76:98-103.
12. Giovannucci E, Pollak M, Platz EA, et al. Insulin-like growth factor I (IGF-I), IGF-binding protein-3 and the risk of colorectal adenoma and cancer in the Nurses' Health Study. Growth Horm IGF Res 2000;10:S30-S31.
13. Giovannucci E, Pollak MN, Platz EA, et al. A prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women. Cancer Epidemiol Biomarkers Prev 2000;9:345-349.
14. Ma J, Pollak M, Giovannucci E, et al. A prospective study of plasma levels of insulin-like growth factor I (IGF-I) and IGF-binding protein-3, and colorectal cancer risk among men. Growth Horm IGF Res 2000;10:S28-S29.
15. Jenkins PJ. Acromegaly and colon cancer. Growth Horm IGF Res 2000;10:S35-S36.
16. Ritter MM, Richter WO, Schwandt P. Acromegaly and colon cancer. Ann Intern Med 1987;106:636-637.
17. Ituarte EA, Petrini J, Hershman JM. Acromegaly and colon cancer. Ann Intern Med 1984;101:627-628.
18. Guo YS, Narayan S, Yallampalli C, Singh P. Characterization of insulin-like growth factor I receptors in human colon cancer. Gastroenterology 1992;102:1101-1108.
19. Koenuma M, Yamori T, Tsuruo T. Insulin and insulin-like growth factor 1 stimulate proliferation of metastatic variants of colon carcinoma 26. Jpn J Cancer Res 1989;80:51-58.
20. Wu Y, Cui K, Miyoshi K, et al. Reduced circulating insulin-like growth factor I levels delay the onset of chemically and genetically induced mammary tumors. Cancer Res 2003;63:4384-4388.
21. Moore T, Carbajal S, Beltran L, et al. Reduced susceptibility to two-stage skin carcinogenesis in mice with low circulating insulin-like growth factor I levels. Cancer Res 2008;68:3680-3688.
22. Wu Y, Yakar S, Zhao L, Hennighausen L, LeRoith D. Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis. Cancer Res 2002;62:1030-1035.
23. Olivo SE, Hilakivi-Clarke L. Opposing effects of prepubertal low- and high-fat n-3 polyunsaturated fatty acid diets on rat mammary tumorigenesis. Carcinogenesis 2005;26:1563-1572.
24. Bland JM, Altman DG. Multiple significance tests: The Bonferroni method. Br Med J 1995;310:170.
25. Reddy BS. Studies with the azoxymethane-rat preclinical model for assessing colon tumor development and chemoprevention. Environ Mol Mutagen 2004;44:26-35.
26. Raju J. Azoxymethane-induced rat aberrant crypt foci: Relevance in studying chemoprevention of colon cancer. World J Gastroenterol 2008;14:6632-6635.
27. Papanikolaou A, Wang QS, Delker DA, Rosenberg DW. Azoxymethane-induced colon tumors and aberrant crypt foci in mice of different genetic susceptibility. Cancer Lett 1998;130:29-34.
28. Ealey KN, Xuan W, Lu S, Archer MC. Colon carcinogenesis in liver-specific IGF-I-deficient (LID) mice. Int J Cancer 2008;122:472-476.
29. Chung H, Wu D, Gay R, et al. Effect of age on susceptibility to azoxymethane-induced colonic aberrant crypt foci formation in C57BL/6JNIA mice. J Gerontol A Biol Sci Med Sci 2003;58:B400-B405.
30. Hong MY, Chapkin RS, Morris JS, et al. Anatomical site-specific response to DNA damage is related to later tumor development in the rat azoxymethane colon carcinogenesis model. Carcinogenesis 2001;22:1831-1835.
31. Nambiar PR, Girnun G, Lillo NA, Guda K, Whiteley HE, Rosenberg DW. Preliminary analysis of azoxymethane induced colon tumors in inbred mice commonly used as transgenic/knockout progenitors. Int J Oncol 2003;22:145-150.